⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15954338 | 0.85 | — | — | |
| SCHEMBL9200574 | 0.80 | PRMT5 (0.30) | — | |
| SCHEMBL578731 | 0.77 | SPHK1 (0.45) | — | |
| SCHEMBL29124812 | 0.77 | MEN1 (0.48) | — | |
| SCHEMBL470896 | 0.77 | — | — | |
| SCHEMBL10684690 | 0.77 | NPC1 (0.33) | — | |
| SCHEMBL10040755 | 0.77 | — | — | |
| SCHEMBL14763933 | 0.77 | SPHK1 (0.39) | — | |
| SCHEMBL18784309 | 0.76 | — | — | |
| SCHEMBL18784343 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3577118-B1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | GILEAD SCIENCES INC (US) | 2024-09-04 | — | — | EP | disclosed |
| US-20200054644-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA BIO, Inc. | 2020-02-20 | — | — | US | disclosed |
| US-10442804-B2 | Compounds for the treatment of hepatitis B virus infection | GILEAD SCIENCES, INC. (US) | 2019-10-15 | — | — | US | disclosed |
| US-20180251460-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | GILEAD SCIENCES, INC. | 2018-09-06 | — | — | US | disclosed |
| WO-2018144605-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | GILEAD SCIENCES, INC. (US) | 2018-08-09 | — | — | WO | disclosed |
| US-20180133225-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA BIO, Inc. | 2018-05-17 | — | — | US | disclosed |
| US-9877970-B2 | Therapeutic compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-9827248-B2 | Therapeutic compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-20160235761-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA BIO, Inc. | 2016-08-18 | — | — | US | disclosed |
| US-20160235761-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA BIO, Inc. | 2016-08-18 | — | — | US | disclosed |
| US-20160237093-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA BIO, Inc. | 2016-08-18 | — | — | US | disclosed |
| US-20160237093-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA BIO, Inc. | 2016-08-18 | — | — | US | disclosed |
| US-9353122-B2 | Therapeutic compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9353122-B2 | Therapeutic compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20140235634-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA PHARMACEUTICALS, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140235634-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA PHARMACEUTICALS, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| WO-2014127214-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA PHARMACEUTICALS, INC. (US) | 2014-08-21 | — | — | WO | disclosed |